Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0021843 (
bowel obstruction
)
9,927
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Motility dysfunction is present not only during
bowel obstruction
(BO), but after obstruction is resolved. Previous studies found that lumen distension associated mechano-transcription of COX-2 and production of PGE
2
in gut smooth muscle cells (SMC) account for motility dysfunction during obstruction. We hypothesized that PGE
2
may exert autocrine effect in SMC to induce
microsomal prostaglandin E synthase-1
(
mPGES-1
), which contributes to motility dysfunction after obstruction is resolved. Partial colon obstruction was induced in rats with an obstruction band, which was released 7 days later. Rats were further studied in the post-BO state. Circular muscle contractility of the mid colon (previously distended during obstruction) remained suppressed, and colon transit was impaired in the post-BO state. The COX-2,
mPGES-1
, and PGE
2
levels were all increased in the distended bowel during obstruction. However, after obstruction was resolved, COX-2 expression returned to normal, whereas
mPGES-1
and PGE
2
levels remained increased. Expression of
mPGES-1
in colon SMC was inducible by stretch or PGE
2
. Administration of
mPGES-1
inhibitor Cay 10526 either before or after the release of obstruction normalized PGE
2
levels and improved motility in the post-BO rats. In conclusion,
mPGES-1
plays a critical role in the continuous suppression of motor function in the post-BO state.
...
PMID:Microsomal Prostaglandin E Synthase-1 Plays a Critical Role in Long-term Motility Dysfunction after Bowel Obstruction. 2989 60
